StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho Downgrades Acadia Pharmaceuticals (ACAD) to Neutral, 'Disappointing ADVANCE-2 Data'
March 12, 2024 2:23 AM
(Updated - March 12, 2024 3:40 AM EDT)Mizuho analyst Uy Ear downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Next Articles
Acadia Pharmaceuticals (ACAD) Stock Selloff Is Over Done Says UBS, 'the level of sell-off is surprising to us'
March 12, 2024 4:07 PM
Acadia Pharma (ACAD) to stop pimavanserin trials after failure
March 12, 2024 12:52 PM
Mizuho Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
March 12, 2024 4:51 AM
Acadia Pharmaceuticals (ACAD) PT Lowered to $39 at JMP Securities
March 12, 2024 2:49 AM
After-hours movers: Oracle surges, Acadia Pharma slumps
March 11, 2024 4:49 PM
Acadia Pharma (ACAD) to Resume Trading at 4:35 p.m., Study Did Not Meet Primary Endpoint
March 11, 2024 4:10 PM
Form 8-K ACADIA PHARMACEUTICALS For: Mar 11
March 11, 2024 4:06 PM
Acadia Pharma (ACAD) Reports Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin
March 11, 2024 4:05 PM
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
March 11, 2024 4:05 PM
Acadia Pharma (ACAD) Halted, News Pending
March 11, 2024 4:01 PM
